Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by O’Shaughnessy, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O’Shaughnessy, J. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:983, 2002
© 2002 European Society for Medical Oncology

Letters to the Editor

Potential of capecitabine as first-line therapy for metastatic breast cancer: dosing recommendations in patients with diminished renal function

J. A. O’Shaughnessy

Baylor-Sammons Cancer Centre, US Oncology, Dallas, TX, USA (E-mail: joyce.o’shaughnessy@usoncology.com)

The randomized phase II trial that we recently reported in this journal [1] demonstrated that the novel oral fluoropyrimidine, capecitabine, achieves similar efficacy to intravenous CMF (cyclophosphamide, methotrexate, 5-fluorouracil) in women >=55 years of age with previously untreated metastatic breast cancer. Although the trial . . . [Full Text of this Article]

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?